Evidence map›Paper›PMID 34477310›Full record

ArticleCancer medicine2021

Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.

Fumiko Arakawa, Hiroaki Miyoshi, Noriaki Yoshida, Kazutaka Nakashima, Yosaku Watatani, Takuya Furuta, Kyohei Yamada, Mayuko Moritsubo, Mai Takeuchi, Eriko Yanagida and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Fumiko ArakawaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID 0000-0003-2998-056X
Hiroaki MiyoshiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID 0000-0002-2356-3725
Noriaki YoshidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID 0000-0001-7001-0106
Kazutaka NakashimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Yosaku WatataniDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.
Takuya FurutaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kyohei YamadaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Mayuko MoritsuboDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID 0000-0002-3382-0473
Mai TakeuchiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Eriko YanagidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Yasumasa ShimasakiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kei KohnoDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Keisuke KataokaDivision of Hematology Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kurume University · JPKeio University · JPKindai University Hospital · JP

Funding

Grant-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science, and Technology of Japan 17K08751
6 · The paper itself

Abstract

Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activation of telomerase. We performed a molecular and pathological analysis of the TERT against three different peripheral T-cell lymphoma (PTCL) subtypes: PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and adult T-cell leukemia/lymphoma (ATLL). Immunohistochemical analysis demonstrated TERT expression in 31% of AITL, 11% of PTCL-NOS, and 5% of ATLL. Among them, AITL frequently showed high TERT expression with statistical significance. TERT promoter mutation analysis and genomic copy number evaluation were performed. TERT promoter mutation was observed in two cases of PTCL-NOS (2/40) and not in other PTCLs. Genome copy number amplification was detected in 33% of PTCL-NOS, 33% of AITL, and 50% of ATLL cases. We evaluated the relationship between the analyzed TERT genomic abnormalities and protein expression; however, no apparent relationship was observed. Furthermore, immunostaining showed TERT expression in the PTCL cytoplasm, suggesting the existence of mechanisms other than the maintenance of telomere length. Statistical analysis of the effect of TERT expression on the prognosis in PTCL cases revealed that TERT expression tended to have a poor prognosis in PTCL-NOS. Since TERT expression was not an independent factor in multivariate analysis, further research will be needed to clarify the poor prognosis of PTCL-NOS in TERT expression.

Indexed as

FemaleHumansImmunohistochemistryLymphoma, T-Cell, PeripheralMaleSurvival AnalysisTelomeraseTelomerasecopy number assayimmunohistochemistrymutation analysisperipheral T-cell lymphomatelomerase reverse transcriptase

Identifiers

PMID34477310
PMCPMC8495278
OpenAlexW3196869071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.